"Sinochem (1762) benefited from the US customer and the original fish oil-related drug Vascepa won the lawsuit, and the purchase of EPA raw materials will be enlarged in the future. It is initially estimated that the additional order from customers exceeds 45 tons, which will drive the performance of the fourth quarter. The stock price last Friday Although it fell slightly by 0.2 yuan, it closed at 66.5 yuan. Although the KD indicator has vacated, but the fundamentals are favorable, it is hoped that the base will be successfully attacked at 66 yuan.
Sinochem’s EPA has been registered in the U.S. for a long time. Two of the three major Icosapent Ethyl customers in the U.S. use Sinochem’s APIs. Due to the shortage of production capacity, the company has planned to expand the fish oil raw material production line and will work hard. It will be completed and put into production in the first half of next year, and the annual production capacity will jump to 350 tons in the future."
Market Data 
Markets 
AI
